Compile Data Set for Download or QSAR
Report error Found 157 Enz. Inhib. hit(s) with all data for entry = 9202
TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448883(US10696672, Compound 115 | US11634418, Compound 11...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448878(US10696672, Compound 110 | US11634418, Compound 11...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448871(US10696672, Compound 103 | US11634418, Compound 10...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448872(US10696672, Compound 104 | US11634418, Compound 10...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448771((S)-4-((R)-3-(2-(5,6,7,8-tetrahydro-1,8- | US10696...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448772((S)-4-((R)-3-(2-(5,6,7,8-tetrahydro-1,8- | US10696...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448767(US10696672, Compound 7c | US11634418, Compound 7c)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448768((S)-4-((R)-3-(2-(5,6,7,8-tetrahydro-1,8- | US10696...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448895(US10696672, Compound 127 | US11634418, Compound 12...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448766(US10696672, Compound 7a | US11634418, Compound 7a)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448760((S)-2-(2-chloro-3-fluorobenzamido)-4- | US10696672...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448761((S)-2-(2,6-dichlorobenzamido)-4-((R)- | US10696672...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448757((S)-2-(2,6-dimethylbenzamido)-4-((R)- | US10696672...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448891(US10696672, Compound 123 | US11634418, Compound 12...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448759((R)-2-(2,6-dimethylbenzamido)-4-((R)- | US10696672...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448745(US10696672, Compound 3c | (S)-2-benzamido-4-((R)-3...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448745(US10696672, Compound 3c | (S)-2-benzamido-4-((R)-3...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448736((R)-2-pivalamido-4-((R)-3-(2-(5,6,7,8- | US1069667...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448743((S)-2-((tert-butoxycarbonyl)amino)-4- | US10696672...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448786((S)-2-(4,4-difluorocyclohexane-1- | US10696672, Co...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448787((R)-2-(4,4-difluorocyclohexane-1- | US10696672, Co...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448784((S)-2-(3,5-dichloroisonicotinamido)-4- | US1069667...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448785((R)-2-(3,5-dichloroisonicotinamido)-4- | US1069667...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448914(US10696672, Compound 146 | US11634418, Compound 14...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448782((S)-2-(isonicotinamido)-4-((R)-3-(2- | US10696672,...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448908(US10696672, Compound 141 | US10696672, Compound 14...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448779((S)-2-(3-morpholinobenzamido)-4- | US10696672, Com...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448776((S)-2-(3-(3,5-dimethyl-1H-pyrazol-1- | US10696672,...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448777((R)-2-(3-(3,5-dimethyl-1H-pyrazol-1- | US10696672,...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448776((S)-2-(3-(3,5-dimethyl-1H-pyrazol-1- | US10696672,...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448777((R)-2-(3-(3,5-dimethyl-1H-pyrazol-1- | US10696672,...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448774((S)-2-(2,6-dichlorobenzamido)-4-((R)- | US10696672...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448802(US10696672, Compound 35 | US11634418, Compound 35)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448804(US10696672, Compound 36 | US11634418, Compound 36)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448798((S)-2-(benzo[d]oxazole-5- | US10696672, Compound 3...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448799((R)-2-(benzo[d]oxazole-5- | US10696672, Compound 3...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448796((S)-2-(1-(difluoromethyl)-1H-indazole- | US1069667...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448797((S)-2-(1-(difluoromethyl)-1H-indazole- | US1069667...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448794((S)-2-(1-methyl-1H-indazole-4- | US10696672, Compo...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448795((S)-2-(1-methyl-1H-indazole-7- | US10696672, Compo...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448793((S)-2-(1H-indazole-7-carboxamido)-4- | US10696672,...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448791((S)-2-(1-methyl-1H-indazole-6- | US10696672, Compo...)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448819(US10696672, Compound 51 | US11634418, Compound 51)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448817(US10696672, Compound 49 | US11634418, Compound 49)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448818(US10696672, Compound 50 | US11634418, Compound 50)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448815(US10696672, Compound 47 | US11634418, Compound 47)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448816(US10696672, Compound 48 | US11634418, Compound 48)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448813(US10696672, Compound 45 | US11634418, Compound 45)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448814(US10696672, Compound 46 | US11634418, Compound 46)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM448811(US10696672, Compound 43 | US11634418, Compound 43)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αvβ6 (2 ug/ml) in PBS (100 ul/well 25° C., overnight). The coating solution was rem...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/2/2021
Entry Details
Go to US Patent

Displayed 1 to 50 (of 157 total ) | Next | Last >>
Jump to: